middle.news
Radiopharm Theranostics Hits 90% Concordance in Brain Metastases Imaging Trial
9:42am on Tuesday 24th of March, 2026 AEDT
•
Healthcare
Read Story
Radiopharm Theranostics Hits 90% Concordance in Brain Metastases Imaging Trial
9:42am on Tuesday 24th of March, 2026 AEDT
Key Points
90% concordance between RAD 101 PET imaging and MRI in 20 patients
Early six-month follow-up data shows positive sensitivity and specificity trends
RAD 101 targets fatty acid synthase, a novel approach for brain metastases imaging
FDA Fast Track designation supports expedited development
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Radiopharm Theranostics (ASX:RAD)
OPEN ARTICLE